Earlier syringe development may cut time-to-market, increase clinical trial appeal Ravensburg, Germany, April 9, 2014 / B3C newswire / – Vetter, a leading contract development and manufacturing ...
Safety, tolerability through 24 months was consistent with 12-month tofacitinib analysis. The approval for Idacio was based on a review of data that showed similar pharmacokinetics, efficacy, safety, ...
Vetter has introduced two clinical syringe packages that make it easier to start syringe development earlier in the drug development process. Starting syringe work earlier, in full or partial parallel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results